Advaxis to Host Business Update and First Quarter 2018 Financial Results Conference Call on March 12, 2018
March 09 2018 - 8:00AM
Business Wire
Advaxis, Inc. (NASDAQ:ADXS), a late-stage
biotechnology company focused on the discovery, development and
commercialization of cancer immunotherapies, announced today the
upcoming release of financial results for the three months ended
January 31, 2018, to take place on Monday, March 12, 2018.
Advaxis’ senior management will host a conference call to review
its financial results and provide a business update. The conference
call and live audio webcast will begin at 4:30 p.m. Eastern time on
Monday, March 12, 2018.
Conference Call & Webcast
InformationWHEN: Monday, March 12, 2018 at 4:30 p.m.
Eastern time.DOMESTIC DIAL-IN: (844) 348-6133INTERNATIONAL DIAL-IN:
(631) 485-4564CONFERENCE ID: 2588455WEBCAST:
ir.advaxis.com/events-presentations
For those unable to participate in the live conference call or
webcast, a digital recording will be available beginning March 12,
2018 two hours after the close of the conference call. To access
the recording, dial (855) 859-2056 or (404) 537-3406 and provide
the operator with the conference ID: 2588455. In addition, the
audio webcast will be archived on the Company’s website for a
period of time at
ir.advaxis.com/events-presentations/events-calendar.
About Advaxis, Inc.
Advaxis, Inc. is a late-stage biotechnology company focused on
the discovery, development and commercialization of proprietary
Lm-based antigen delivery products. These immunotherapies are based
on a platform technology that utilizes live attenuated Listeria
monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion
proteins. These Lm-based strains integrate multiple functions into
a single immunotherapy, and are designed to access and direct
antigen presenting cells to stimulate anti-tumor T cell immunity,
activate the immune system with the equivalent of multiple
adjuvants and simultaneously reduce tumor protection in the tumor
microenvironment to enable the T cells to eliminate tumors. Advaxis
has four franchises in various stages of clinical and near-clinical
development: HPV-associated cancers, individualized neoantigen
immunotherapy, cancer-specific hotspot mutation immunotherapies and
prostate cancer.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180309005131/en/
Company:Advaxis, Inc.Noelle Heber, 609-250-7575Sr.
Director Corporate Communications and Government
AffairsHeber@advaxis.comorMedia:Stern Strategy GroupBrian
Hyland, 908-325-3891Bhyland@sternstrategy.comorRachel Auerbach,
908-325-3898Rauerbach@sternstrategy.comorInvestors:LHA
Investor RelationsAnne Marie Fields,
212-838-3777afields@lhai.com
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Sep 2023 to Sep 2024